Clinical Trials Browser

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT00102544 2026-04-08

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

Phase NA Enrolling by invitation

3,894 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Prostatic Neoplasms

NCT07405164 2026-03-31

MK-6482-043

Phase 3 Recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT04074135 2026-02-24

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Phase 2 Recruiting

740 enrolled

EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

100 enrolled

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT03401788 2024-12-03

MK-6482-004

Phase 2 Active not recruiting

50 enrolled 2 FDA

von Hippel-Lindau Disease

NCT03108066 2024-09-24

MK-3795-003

Phase 2 Completed

4 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT06553339 2024-08-14

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Phase 1 Recruiting

60 enrolled

von Hippel-Lindau Disease, Neuroectodermal Tumors, Primitive

NCT00330564 2024-06-27

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

Phase 2 Terminated

15 enrolled 5 charts

Genitourinary

Carcinoma, Renal Cell, Cysts, von Hippel-Lindau Disease, Neoplasms, Hemangioblastoma

NCT05424016 2023-12-13

PRO-HEB

Phase NA Recruiting

85 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

NCT05843305 2023-05-06

A Study of BPI-452080 in Subjects With Solid Tumors

Phase 1 Unknown

87 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Phase EARLY_PHASE1 Terminated

4 enrolled

CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT01967537 2019-11-19

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Phase 2 Completed

341 enrolled 14 charts

EndocrineNET

von Hippel-Lindau Disease, Neuroendocrine Tumors

NCT02108002 2018-09-14

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

Phase 1 Completed

7 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

NCT00089765 2017-07-02

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Phase 1 Completed

5 enrolled

von Hippel-Lindau Disease, Macular Edema, Neoplasms

NCT00052013 2017-03-06

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

Phase 2 Completed

11 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

NCT01266070 2017-02-13

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Phase 2 Terminated

6 enrolled 5 charts

CNS

von Hippel-Lindau Disease, Central Nervous System Neoplasms, Hemangioblastoma

NCT00088374 2012-07-27

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

Phase 2 Completed

9 enrolled 8 charts

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Kidney Neoplasms

NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Phase EARLY_PHASE1 Terminated

1 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

NCT00056199 2008-03-04

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Phase 1 Completed

5 enrolled

von Hippel-Lindau Disease, Macular Edema, Vision Disorders, Optic Nerve Neoplasms

Clinical Trials

MK-6482-015

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

MK-6482-043

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

BELIEVE-VHL

MK-6482-004

MK-3795-003

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

PRO-HEB

A Study of BPI-452080 in Subjects With Solid Tumors

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome